Analysis Of Income And Expense [Abstract]

Transgene - Filing #6250839

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Analysis of income and expense [abstract]
Material income and expense [abstract]
Research and development expense	34 278 EUR	—	—	—	—	—	—	—	29 588 EUR	—	—	—	—	—
Finance income (cost)	1 687 EUR	—	—	—	—	—	—	—	7 719 EUR	—	—	—	—	—
Selling, general and administrative expense [abstract]
General and administrative expense	7 761 EUR	—	—	—	—	—	—	—	6 987 EUR	—	—	—	—	—
Revenue and other operating income	6 353 EUR	—	—	—	—	—	—	—	7 900 EUR	—	—	—	—	—
Operating expense	42 011 EUR	—	—	—	—	—	—	—	37 947 EUR	—	—	—	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	3,000 EUR	- EUR	- EUR	- EUR	- EUR	- EUR	3,000 EUR	- EUR	7,000 EUR	- EUR	- EUR	- EUR	- EUR	7,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	33 775 EUR	33 971 EUR	- EUR	- EUR	- EUR	- EUR	196,000 EUR	- EUR	22 520 EUR	- EUR	22 328 EUR	- EUR	- EUR	192,000 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	33 775 EUR	—	—	—	—	—	—	—	22 520 EUR	—	—	—	—	—
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests	- EUR	—	—	—	—	—	—	—	- EUR	—	—	—	—	—